Compare NIU & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | DYN |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.6M | 2.8B |
| IPO Year | 2018 | 2020 |
| Metric | NIU | DYN |
|---|---|---|
| Price | $3.45 | $15.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $39.94 |
| AVG Volume (30 Days) | 462.5K | ★ 1.9M |
| Earning Date | 03-16-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $625,182,280.00 | N/A |
| Revenue This Year | $42.51 | N/A |
| Revenue Next Year | $17.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.99 | N/A |
| 52 Week Low | $2.11 | $6.36 |
| 52 Week High | $5.67 | $25.00 |
| Indicator | NIU | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 37.26 |
| Support Level | $3.36 | $15.80 |
| Resistance Level | $3.58 | $17.45 |
| Average True Range (ATR) | 0.19 | 0.99 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 56.15 | 6.93 |
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.